Nang Kuang Pharmaceutical Co., Ltd. announced that the Abbreviated New Drug Application (ANDA) for Pemetrexed for Injection indicated for the treatment of lung cancer has been final approved by the U.S. Food and Drug Administration (FDA). The drug will be immediately launched in the U.S. to increase the revenue.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
44.6 TWD | -0.89% | +0.11% | -16.32% |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-16.32% | 140M | |
+26.08% | 662B | |
+21.85% | 546B | |
-4.77% | 359B | |
+16.97% | 323B | |
+5.69% | 290B | |
+13.68% | 234B | |
+3.65% | 198B | |
-11.12% | 194B | |
-3.40% | 157B |
- Stock Market
- Equities
- 1752 Stock
- News Nang Kuang Pharmaceutical Co., Ltd.
- Nang Kuang Pharmaceutical Co., Ltd. Receives Final U.S. FDA Approval for Its ANDA